All In Biotech

Drug Trial Radar · NCT04654741

The Rate of Embryo Euploidy in Progestin-primed Ovarian Stimulation Cycles

The Rate of Embryo Euploidy in Women Treated With Progestin-primed Ovarian Stimulation Versus Conventional Ovarian Stimulation: a Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Dec 4, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 396 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

396

Planned (sponsor's estimate)

Start

Sep 1, 2020

Primary completion

Feb 1, 2022

Study completion Dec 31, 2022

Sponsor

Lead sponsor
Casa di Cura Privata Villa MafaldaResearch network
Sponsor type
Research network
First posted
Dec 4, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of this non-inferiority randomized controlled trial is to assess the rate of blastocyst euploidy and the number of euploid blastocysts in women undergoing IVF/ICSI and treated with PPOS versus conventional ovarian stimulation based on the use of GnRH antagonist The hypothesis is that PPOS is associated with a rate of blastocyst euploidy similar to what found with the conventional ovarian stimulation. In other words, the number of euploid blastocysts that can be obtained with the PPOS strategy is expected to be the same obtained with conventional ovarian stimulation. Moreover we expect to find non significant differences in all intermediate outcome of the IVF cycles, such as in the rate of premature LH surge, in the rate of patients with elevation of Progesterone on the triggering day, in FSH consumption and length of stimulation, in the rate of poor response and hyperresponse, in number of retrieved and mature oocytes, in fertilization and blastulation rate, in the number of available blastocysts and in the morphological quality of blastocysts

Conditions

  • IVF
  • Infertility

Interventions

  • Medroxyprogesterone AcetateDrug

    1 pill per day

  • Ganirelix AcetateDrug

    1 injection per day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. blastocyst euploidyTime frame: From the date of randomization up to the assessment of blastocyst euploidy (up to 20 weeks)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Villa Mafalda

    Roma, Italy · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.